



---

...

**13.1.1**

...TNF...TNF...  
...0.8mg/kg...50mg/...2...0.4mg/kg  
...25mg...2...  
...  
...  
...JIA  
...

**13.1.2 Infliximab**

...Infliximab...  
...  
...Infliximab...8...1...6mg/kg...  
...  
...3mg/kg/  
...  
...  
...Infliximab...

**13.1.3**

...  
...  
...2...1...24mg/m2/...40mg/...  
...  
...  
...  
...A...

**13.2**

**13.2.1 Abatacept**

...Abatacept...T...CTL4Ig...

---

Abatacept 1-6mg/kg / Abatacept TNF

### 13.2.2 Anakinra

Anakinra IL-1 IL-1 cryopirin CAPS 1-2mg/kg 5mg/kg 100mg JIA 2 cryopirin CAPS

### 13.2.3 Canakinumab

Canakinumab 1(IL1) cryopirin (CAPS) 1-4mg/kg cryopirin (CAPS)

### 13.2.4

6 IL6 JIA 15-30kg 8mg/kg 30kg 12mg/kg 4-10mg/kg JIA ( )

### 13.3

---

rituximab (anti-CD20) tofacitinib (JAK-3 inhibitor) and other immunosuppressants. The use of these drugs is associated with an increased risk of infection, including opportunistic infections and reactivation of latent viruses. Patients should be monitored for signs and symptoms of infection and should avoid contact with sick individuals. Live vaccines should be avoided while on these medications.